NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-07-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00006442

Locations: 🇺🇸
Michael S. Saag, Birmingham, Alabama, United States

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000896

Locations: 🇺🇸
Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Not Applicable

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT00000703

Locations: 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States

and more 11 locations

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00001133

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States

and more 4 locations

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Phase 3

Completed

Conditions: End-Stage Renal Disease
Kidney Transplantation

Interventions: Biological: Intravenous immune globulin (IVIG)

First Posted Date: 2001-08-31

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000935

Locations: 🇺🇸
Ann Limberger, Rockville, Maryland, United States

A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000662

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Not Applicable

Completed

Conditions: HIV Infections
Cytomegalovirus Retinitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00000989

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

and more 1 locations

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00000952

Locations: 🇺🇸
Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States
🇺🇸
The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸
HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States

and more 9 locations

A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

Phase 1

Withdrawn

Conditions: Encephalopathy
Radiculitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000856

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Phase 1

Completed

Conditions: HIV Infections
Pregnancy

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT00000888

Locations: 🇺🇸
Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States
🇺🇸
Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States
🇺🇸
Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy